Sign inJoin waitlistJoin the waitlist

David Zhen

Associate Professor, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Michigan
2014–2017
Internal Medicine
Mayo Clinic
2011–2014
Wayne State University School of Medicine
2007–2011

Research

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
The Lancet. Gastroenterology & hepatology · 2024 · 275 citations
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Genetics in Medicine · 2015 · First of 18 authors · 239 citations
Hereditary ATTR amyloidosis: a single-institution experience with 266 patients
Amyloid · 2015 · 86 citations

EC
Elena Chiorean
11 papers
Andrew Coveler
8 papers
Gentry King
6 papers
Rachael Safyan
5 papers
MZ
Mark Zalupski
4 papers
Stacey Cohen
4 papers
Vaibhav Sahai
4 papers
Veena Shankaran
4 papers
Venu Pillarisetty
4 papers
William Harris
4 papers
Lindsay Hannan
3 papers
Aiwu He
2 papers

Clinical trials

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
Principal investigator · Not yet recruiting · Phase 1
Medigene AG
2025–2042
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Principal investigator · Suspended · Phase 2, Phase 3
National Cancer Institute (NCI)
2022–2028
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Principal investigator · Active not recruiting · Phase 2
University of Washington
2019–2026
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Site PI · Recruiting · Phase 1, Phase 2
A2 Biotherapeutics Inc.
2024–2029